Sparks - Herantis Pharma

Herantis Pharma has announced that it has successfully completed its six-month preclinical toxicology study for lead clinical candidate HER-096, which is being developed as a potentially disease-modifying treatment for Parkinson’s disease. The outcome of this study confirmed the favourable safety and tolerability profile of HER-096, consistent with prior preclinical and clinical data. This marks a key step in the clinical development of the candidate, and management is preparing for Phase II, which it plans to launch in 2026.

Most recently from the clinic, HER-096 completed a Phase Ib trial, meeting its primary and secondary endpoints. More detailed biomarker data are anticipated in January 2026, and Herantis will present the results at the JP Morgan Healthcare Conference.

The latest update also noted the completion of the toxicology study marks the conclusion of Herantis’s EIC Accelerator Grant project, which commenced in 2023.  The grant, comprising €2.5m, also allowed the company to advance the biomarker development programme, as part of the Phase Ib programme.